Metaglip
Metaglip
Metaglip (pronounced: meh-tuh-glip) is a prescription medication used in the treatment of Type 2 diabetes. It is a combination of two active ingredients: glipizide and metformin.
Etymology
The name "Metaglip" is a portmanteau of the names of its two active ingredients, "metformin" and "glipizide".
Usage
Metaglip is used alongside a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. It is used when diet and exercise alone does not result in the desired blood sugar control.
Mechanism of Action
Metaglip combines two antidiabetic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes:
- Glipizide lowers blood glucose primarily by stimulating the release of insulin from the pancreas.
- Metformin hydrochloride, an antihyperglycemic agent, improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose.
Side Effects
Common side effects of Metaglip include nausea, upset stomach, diarrhea, and dizziness. More serious side effects can include lactic acidosis, low blood sugar, and skin rash.
Related Terms
- Type 2 diabetes
- Glipizide
- Metformin
- Antidiabetic agents
- Blood glucose
- Insulin
- Pancreas
- Lactic acidosis
External links
- Medical encyclopedia article on Metaglip
- Wikipedia's article - Metaglip
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski